{
    "title": "110_hr3334",
    "content": "The \"SMA Treatment Acceleration Act\" is the short title of this Act. The Congress finds that spinal muscular atrophy (SMA) is the top genetic killer of children under 2, causing nerve destruction affecting muscle movement. SMA occurs in 1 of every 6,000 births, similar to cystic fibrosis and Duchenne muscular dystrophy. SMA is advantageous for genetic screening and therapy due to a single gene mutation. The gene mutation causing SMA affects approximately 7,500,000 Americans. Discovering the SMN1 gene and SMN2 gene has led to new treatments for SMA and other genetic disorders. Modulating these genes could impact conditions like Duchenne Muscular Dystrophy, Parkinson's, and Alzheimer's disease. Success with SMN2 induction in SMA will drive research in other genetic conditions. The National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS) selected Spinal Muscular Atrophy (SMA) as the prototype for their accelerated drug discovery effort. In 2003, NINDS established the SMA Project to accelerate therapeutics development through a collaborative process involving private, public, and non-profit partners. This model translational research program aims to expedite the development of safe and effective treatments for various disorders. National non-profit organizations collaborate with biotechnology and pharmaceutical companies to find treatments for SMA. They invest resources equal to the Federal Government annually. An FDA-approved animal model for SMA exists, with effective therapeutics identified in animal studies. There is an urgent need for Federal support to conduct national clinical trials for spinal muscular atrophy (SMA) treatments. Establishing a national clinical trials network and data coordinating center will allow for rigorous patient evaluation and faster answers. Greater interagency coordination and involvement from government partners are needed to support SMA research efforts. The need for active engagement by various organizations, including NICHD, for diseases like SMA is emphasized. Additional incentives for industry involvement in drug development are necessary. Educating the public and healthcare community about SMA is crucial. Greater awareness of SMA is crucial as it may help identify pre-symptomatic children with the disease, leading to significant benefits in clinical trials and the search for a treatment and cure. The text chunk \"SEC. 3. CLINICAL TRIALS NETWORK FOR SPINAL MUSCULAR ATROPHY.\" is about establishing a clinical trials network for spinal muscular atrophy. The Director of NIH will establish a national clinical trials network for SMA to conduct coordinated trials and disseminate findings efficiently. Additionally, a data coordinating center will be established for SMA. The data coordinating center for SMA will provide expert assistance in research project design, data analysis, biostatistics, and project management. It will also support data collection, quality control systems, monitoring activities, and reporting to the National Institute of Health. The Director of NIH, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development, will expand pre-clinical translation research and medicinal chemistry programs related to SMA. Regular reports on enrollment and resource allocation will be provided to the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development. The Secretary of Health and Human Services will enhance the existing SMA patient registry for expanded research on SMA epidemiology, collecting longitudinal data on individuals of all ages with SMA. Additionally, a NIH Coordinating Committee on SMA will be established. The Secretary will establish the Spinal Muscular Atrophy Coordinating Committee with up to 15 members to coordinate activities across NIH and other federal health programs related to SMA. The Spinal Muscular Atrophy Coordinating Committee will include representatives from various federal departments and agencies involved in health functions relevant to SMA, such as the CDC, FDA, and Department of Education. The Spinal Muscular Atrophy Coordinating Committee will consist of members from federal departments and agencies related to SMA, with 1/3 being public members representing those affected by SMA. Members appointed for a 3-year term can serve unlimited terms if reappointed. The Chair of the Committee will advise key health officials and provide guidance on SMA. The Secretary appoints the Chair of the Coordinating Committee for a maximum of 2 years, with the possibility of one additional term. The Committee receives necessary administrative support and meets as determined by the Secretary. The Coordinating Committee, in consultation with the Chair, conducts a study on barriers to drug development for SMA and similar genetic disorders, considering obstacles from preclinical research to drug approval. The Coordinating Committee will submit a report to Congress within 1 year of the Act's enactment, detailing the study on barriers to drug development for SMA and similar genetic disorders, along with recommendations for legislative or administrative actions. NIH will collaborate on SMA research. The Director of NIH will establish a cooperative research initiative on SMA to support the ongoing needs of the SMA Project led by the National Institute of Neurological Disorders and Stroke. The initiative will involve reporting on project needs and providing direct support for SMA research and drug development. The Director of NIH will promote collaboration in SMA research and drug development by other national research institutes. The Secretary will submit recommendations to Congress to enhance incentives for SMA drug development, including unique incentives for rare pediatric treatments. Additionally, there will be education and awareness initiatives for healthcare professionals on SMA. The Secretary will establish a program to educate health professionals and the public on SMA, including advances in diagnosis and treatment. Stipends may be awarded to professionals in training programs. In this Act, key definitions include the Director of NIH, Coordinating Committee for Spinal Muscular Atrophy, Secretary of Health and Human Services, and spinal muscular atrophy (SMA)."
}